|
DE08786222T1
(de)
*
|
2007-07-31 |
2010-11-25 |
Affibody Ab |
Neue albuminbindende zusammensetzungen, verfahren und anwendungen
|
|
EP2437767B1
(en)
*
|
2009-06-01 |
2015-07-08 |
MedImmune, LLC |
Molecules with extended half-lives and uses thereof
|
|
WO2011110515A1
(en)
*
|
2010-03-08 |
2011-09-15 |
Affibody Ab |
Immunoglobulin g fc region binding polypeptide
|
|
PH12012502018A1
(en)
*
|
2010-04-30 |
2018-03-21 |
Sanwa Kagaku Kenkyusho Co |
Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability
|
|
BR112013000452A2
(pt)
*
|
2010-07-09 |
2020-02-11 |
Affibody Ab |
Polipeptídeo de ligação de albumina, proteína de fusão ou conjugado, polinucleotídeo, método para produzir um polipeptídeo, composição, método para a preparação de uma composição, e, método para aumentar a solubilidade de um composto
|
|
ES2667100T3
(es)
*
|
2010-08-02 |
2018-05-09 |
Macrogenics, Inc. |
Diacuerpos covalentes y sus usos
|
|
MX349054B
(es)
|
2010-09-28 |
2017-07-07 |
Aegerion Pharmaceuticals Inc |
Leptinas altamente solubles.
|
|
BR112013007442A2
(pt)
|
2010-09-28 |
2019-09-24 |
Amylin Pharmaceuticals Llc |
polipeptídeos construídos tendo duração de ação realçada
|
|
EP3514169B1
(en)
|
2010-11-26 |
2024-03-06 |
Molecular Partners AG |
Designed repeat proteins binding to serum albumin
|
|
US9376495B2
(en)
*
|
2011-05-21 |
2016-06-28 |
Macrogenics, Inc. |
Deimmunized serum-binding domains and their use in extending serum half-life
|
|
DK2729160T3
(da)
|
2011-07-08 |
2019-07-01 |
Aegerion Pharmaceuticals Inc |
Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
|
|
JP6006309B2
(ja)
*
|
2011-07-08 |
2016-10-12 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
|
|
KR102149028B1
(ko)
|
2012-02-20 |
2020-08-27 |
스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) |
인간 보체 c5에 결합하는 폴리펩티드
|
|
JP2015512902A
(ja)
*
|
2012-03-28 |
2015-04-30 |
アフィボディ・アーベー |
経口投与
|
|
JP2020033372A
(ja)
*
|
2012-03-28 |
2020-03-05 |
アフィボディ・アーベー |
経口投与
|
|
WO2013148966A1
(en)
*
|
2012-03-28 |
2013-10-03 |
Amylin Pharmaceuticals, Llc |
Transmucosal delivery of engineered polypeptides
|
|
JP2015519345A
(ja)
|
2012-05-25 |
2015-07-09 |
ヤンセン バイオテツク，インコーポレーテツド |
非天然コンセンサスアルブミン結合ドメイン
|
|
US10155792B2
(en)
|
2012-09-25 |
2018-12-18 |
Affibody Ab |
Albumin binding polypeptide
|
|
WO2014053586A1
(en)
|
2012-10-05 |
2014-04-10 |
Affibody Ab |
Her3 binding polypeptides
|
|
PL2912054T3
(pl)
|
2012-10-25 |
2017-11-30 |
Affibody Ab |
Polipeptyd wiążący albuminę
|
|
JP6396303B2
(ja)
*
|
2012-10-25 |
2018-09-26 |
アフィボディ・アーベー |
アルブミン結合を含有するタンパク質の分離方法
|
|
WO2014076179A1
(en)
|
2012-11-14 |
2014-05-22 |
Affibody Ab |
New polypeptide
|
|
USRE48805E1
(en)
|
2013-03-06 |
2021-11-02 |
Vision Global Holdings Ltd. |
Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
|
|
US9255262B2
(en)
*
|
2013-03-06 |
2016-02-09 |
Vision Global Holdings Ltd. |
Albumin-binding arginine deminase and the use thereof
|
|
CA2902789A1
(en)
|
2013-03-14 |
2014-09-18 |
The Governing Council Of The University Of Toronto |
Scaffolded peptidic libraries and methods of making and screening the same
|
|
WO2014140210A1
(en)
|
2013-03-14 |
2014-09-18 |
Pieris Ag |
Novel binding proteins for pcsk9
|
|
MX366425B
(es)
|
2013-03-15 |
2019-07-04 |
Affibody Ab |
Nuevos polipeptidos.
|
|
EP2986306A4
(en)
|
2013-04-18 |
2016-12-07 |
Armo Biosciences Inc |
METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
|
|
CA2914837A1
(en)
|
2013-06-17 |
2014-12-24 |
Armo Biosciences, Inc. |
Method for assessing protein identity and stability
|
|
WO2015028558A1
(en)
|
2013-08-28 |
2015-03-05 |
Swedish Orphan Biovitrum Ab (Publ) |
Stable polypeptides binding to human complement c5
|
|
US9982022B2
(en)
|
2013-08-28 |
2018-05-29 |
Affibody Ab |
Binding polypeptides having a mutated scaffold
|
|
US10010588B2
(en)
|
2013-08-30 |
2018-07-03 |
Armo Biosciences, Inc. |
Methods of using pegylated interleukin-10 for treating hyperlipidemia
|
|
KR20160079114A
(ko)
|
2013-11-11 |
2016-07-05 |
아르모 바이오사이언시스 인코포레이티드 |
질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
|
|
WO2015091957A1
(en)
|
2013-12-20 |
2015-06-25 |
Affibody Ab |
Engineered albumin binding polypeptide
|
|
WO2015187295A2
(en)
|
2014-06-02 |
2015-12-10 |
Armo Biosciences, Inc. |
Methods of lowering serum cholesterol
|
|
JP6704358B2
(ja)
|
2014-07-30 |
2020-06-03 |
エヌジーエム バイオファーマシューティカルズ インコーポレイテッド |
代謝障害を治療するための組成物および使用方法
|
|
US10323066B2
(en)
|
2014-09-17 |
2019-06-18 |
Affibody Ab |
Neonatal Fc receptor binding dimer and methods of use
|
|
EP3206713A4
(en)
|
2014-10-14 |
2018-06-27 |
Armo Biosciences, Inc. |
Interleukin-15 compositions and uses thereof
|
|
AU2015336101A1
(en)
|
2014-10-22 |
2017-04-20 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
CN106687128B
(zh)
|
2014-10-31 |
2022-05-10 |
Ngm生物制药有限公司 |
用于治疗代谢病症的组合物和方法
|
|
KR20240110106A
(ko)
|
2015-01-12 |
2024-07-12 |
애피바디 에이비 |
Il-17a-결합 폴리펩티드
|
|
US10618970B2
(en)
|
2015-02-03 |
2020-04-14 |
Armo Biosciences, Inc. |
Method of treating cancer with IL-10 and antibodies that induce ADCC
|
|
US11052133B2
(en)
|
2015-05-06 |
2021-07-06 |
Protomer Technologies, Inc. |
Glucose responsive insulins
|
|
WO2016191587A1
(en)
|
2015-05-28 |
2016-12-01 |
Armo Biosciences, Inc. |
Pegylated interleukin-10 for use in treating cancer
|
|
US11458205B2
(en)
|
2015-08-04 |
2022-10-04 |
Duke University |
Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
|
|
CA2995120A1
(en)
|
2015-08-25 |
2017-03-02 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
US11752213B2
(en)
|
2015-12-21 |
2023-09-12 |
Duke University |
Surfaces having reduced non-specific binding and antigenicity
|
|
CN107022031A
(zh)
*
|
2016-01-29 |
2017-08-08 |
中国人民解放军军事医学科学院微生物流行病研究所 |
融合蛋白HSA1-Vβ1及其应用
|
|
WO2017210476A1
(en)
|
2016-06-01 |
2017-12-07 |
Duke University |
Nonfouling biosensors
|
|
KR20190064600A
(ko)
|
2016-09-23 |
2019-06-10 |
듀크 유니버시티 |
Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드
|
|
CN107952080A
(zh)
*
|
2016-10-14 |
2018-04-24 |
中国科学院过程工程研究所 |
一种肿瘤靶向多肽-药物偶联衍生物、其制备方法及应用
|
|
US11648200B2
(en)
|
2017-01-12 |
2023-05-16 |
Duke University |
Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
|
|
WO2018213320A1
(en)
|
2017-05-15 |
2018-11-22 |
Duke University |
Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
|
|
EP3658168A4
(en)
|
2017-06-30 |
2021-07-14 |
Duke University |
ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONDING BIOPOLYMER NETWORKS
|
|
CN111164104A
(zh)
|
2017-08-09 |
2020-05-15 |
麻省理工学院 |
白蛋白结合肽缀合物及其方法
|
|
US20200239575A1
(en)
*
|
2017-10-06 |
2020-07-30 |
University Of Utah Research Foundation |
A fusion protein for targeted therapy of autoimmune disease
|
|
WO2019071150A1
(en)
*
|
2017-10-06 |
2019-04-11 |
University Of Utah Research Foundation |
FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE
|
|
WO2019147954A1
(en)
*
|
2018-01-26 |
2019-08-01 |
Duke University |
Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
|
|
EP3765496A1
(en)
|
2018-03-13 |
2021-01-20 |
Affibody AB |
Polypeptides based on a novel scaffold
|
|
WO2019213150A1
(en)
|
2018-04-30 |
2019-11-07 |
Duke University |
Stimuli-responsive peg-like polymer-based drug delivery platform
|
|
EP3829622A4
(en)
|
2018-08-02 |
2022-05-11 |
Duke University |
DOUBLE AGONIST FUSION PROTEINS
|
|
WO2020051541A1
(en)
*
|
2018-09-07 |
2020-03-12 |
Duke University |
Nanoparticulate drug delivery systems
|
|
EP3930687A4
(en)
|
2019-02-25 |
2023-06-07 |
The University of Chicago |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
|
|
KR20220016944A
(ko)
|
2019-06-04 |
2022-02-10 |
몰리큘라 파트너스 아게 |
개선된 안정성을 갖는 설계된 안키린 반복 도메인
|
|
US11512314B2
(en)
|
2019-07-12 |
2022-11-29 |
Duke University |
Amphiphilic polynucleotides
|
|
AU2020342349A1
(en)
|
2019-09-02 |
2022-03-03 |
Biotest Ag |
Factor VIII protein with increased half-life
|
|
EP3785726A1
(en)
|
2019-09-02 |
2021-03-03 |
Biotest AG |
Factor viii protein with increased half-life
|
|
WO2021089695A1
(en)
|
2019-11-05 |
2021-05-14 |
Affibody Ab |
Polypeptides
|
|
WO2021165226A1
(en)
|
2020-02-17 |
2021-08-26 |
Biotest Ag |
Subcutaneous administration of factor viii
|
|
EP3878515A1
(en)
*
|
2020-03-09 |
2021-09-15 |
Hober Biotech AB |
Therapeutic agent targeting her2
|
|
WO2022098743A1
(en)
|
2020-11-03 |
2022-05-12 |
Indi Molecular, Inc. |
Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)
|
|
WO2022098745A1
(en)
|
2020-11-03 |
2022-05-12 |
Indi Molecular, Inc. |
Compositions, delivery systems, and methods useful in tumor therapy
|
|
KR20230123989A
(ko)
|
2020-12-21 |
2023-08-24 |
애피바디 에이비 |
신규 폴리펩티드
|
|
WO2022171892A1
(en)
|
2021-02-15 |
2022-08-18 |
Affibody Ab |
New her2-binding polypeptide
|
|
MX2024009732A
(es)
|
2022-02-08 |
2024-08-19 |
Affibody Ab |
Variantes de la proteina z que enlazan la linfopoyetina estromal timica y su uso medico.
|
|
PE20251287A1
(es)
|
2022-05-18 |
2025-05-14 |
Protomer Tech Inc |
Compuestos aromaticos que contienen boro y analogos de insulina relacionados
|
|
CN119677787A
(zh)
|
2022-08-10 |
2025-03-21 |
兴和株式会社 |
亲和体微胞药物复合体
|
|
IL322519A
(en)
|
2023-02-17 |
2025-10-01 |
Ablynx Nv |
Polypeptides that bind to the neonatal fc receptor
|
|
EP4704911A1
(en)
|
2023-05-04 |
2026-03-11 |
Affibody AB |
New polypeptide
|
|
EP4788689A1
(en)
|
2023-10-03 |
2026-08-12 |
BicycleTx Limited |
Bicyclic peptide ligand complexes specific for tfr1
|
|
WO2025158010A1
(en)
|
2024-01-25 |
2025-07-31 |
Affibody Ab |
Her2-binding polypeptide
|
|
CN121041473A
(zh)
*
|
2024-05-29 |
2025-12-02 |
烟台蓝纳成生物技术股份有限公司 |
一种双功能性融合蛋白、放射性核素标记物及其应用
|
|
CN118666961B
(zh)
*
|
2024-08-23 |
2024-11-26 |
通化安睿特生物制药股份有限公司 |
人白蛋白特异结合多肽及其应用
|
|
WO2026107057A1
(en)
*
|
2024-11-13 |
2026-05-21 |
Biomedit, Inc. |
Stabilized glp-1 peptides and dual agonist peptides against glp-1r and gipr and methods of use thereof
|